Aim: Pruritus is a common comorbidity in chronic liver disease. The aim of this study was to clarify the prevalence of pruritus and its characteristics in patients with chronic liver disease.
INTRODUCTION
Pruritus is a common comorbid symptom of chronic liver disease. 1 The prevalence of pruritus has been reported to be 18-77% in patients with primary biliary cholangitis (PBC), 2-7 5.1-58.4% in patients with hepatitis C virus (HCV) infection, [8] [9] [10] [11] [12] and 8% patients with hepatitis B virus (HBV) infection. 11 The prevalence of pruritus in these chronic liver diseases varies, and has not been confirmed in a large cohort study. In addition, the prevalence of pruritus in patients with autoimmune hepatitis (AIH), alcoholic liver disease (ALD), and non-alcoholic fatty liver disease (NAFLD) remains unknown. Pruritus with chronic liver disease is a refractory symptom and it reduces the patients' quality of life (QOL). [13] [14] [15] However, without enough investigation by physicians and medical personnel, the symptom of pruritus could be missed. To improve the QOL for patients with chronic liver disease, pruritus should be assessed more precisely and a prospective study to identify the characteristics of pruritus in chronic liver diseases is required. Here, we undertook an interview-based survey to clarify the prevalence and features of pruritus in patients with chronic liver disease.
METHODS

Patients
A TOTAL OF 1631 outpatients with various chronic liver diseases who attended one of nine joint-research facilities from January 2016 to June 2016 were included and underwent a medical interview about pruritus.
Patients with overt skin disease including eczema and atopic dermatitis were excluded from the survey.
Evaluation of pruritus
The medical interview was recorded by the physician using an interview form that contained questions about the existence of pruritus, pruritus location on the body, pruritus duration, circadian variation and seasonality of pruritus, use of antipruritic agents, and satisfaction with the treatment. Severity of pruritus was evaluated using a visual analog scale (VAS), 16 which quantitatively showed the degree of pruritus from 0 (no pruritus) to 10 (maximum pruritus), according to the patients' subjective perception of pruritus severity.
Etiology of chronic liver disease
We categorized the patients into 10 chronic liver disease groups, according to the flowchart shown in Figure 1 . Patients with a history of HCV infection (n = 628) were divided into the chronic HCV infection (n = 366) group, which included patients who had positive HCV-RNA results, and the post sustained virologic response (n = 262) group, which included patients who achieved HCV clearance using anti-HCV agents. Patients with a history of HBV infection (n = 229) were divided into two Figure 1 Flowchart of underlying liver disease categories in 1631 patients. AIH, autoimmune hepatitis; HBV, hepatitis B virus; HCV, hepatitis C virus; NAFLD, non-alcoholic fatty liver disease; PBC, primary biliary cholangitis; SVR, sustained virologic response.
groups. We defined the hepatitis B envelope antigenpositive/negative immune-active phase as the active HBV infection (n = 175) group, and the inactive phase as the inactive HBV carrier (n = 54) group. 17 There were no patients within the immune-tolerant phase in this study. Patients with HCV and HBV co-infection (n = 6) were categorized in the chronic HCV infection group. In patients without a history of HCV or HBV infection (n = 774), patients who had habitual alcohol intake (n = 76) were categorized with the ALD group, and the other patients were categorized with PBC (n = 72), AIH (n = 70), overlap syndrome (PBC + AIH, n = 10), or NAFLD (n = 338) groups, according to the individual diagnostic guidelines [18] [19] [20] [21] and clinical diagnosis by the physician in charge. (14.4) †Data are presented as the median (interquartile range). ‡Data are presented as a positive number (%).
-, Not applicable. AIH, autoimmune hepatitis; ALB, albumin; ALD, alcoholic liver disease; ALT, alanine aminotransferase; APRI, aspartate aminotransferase-to-platelet ratio index; AST, aspartate aminotransferase; BUN, blood urea nitrogen; Cr, creatinine; D-BIL, direct bilirubin; eGFR, estimated glomerular filtration rate; FIB-4, Fibrosis-4; HbA1c, hemoglobin A1c; HBV, hepatitis B virus; HCV, hepatitis C virus; NAFLD, nonalcoholic fatty liver disease; PBC, primary biliary cholangitis; PLT, platelet count; PT%, prothrombin time activity; PT-INR, international normalized ratio of prothrombin time; SVR, sustained virologic response; T-BIL, total bilirubin; UA, uric acid.
Patients who did not meet these criteria, such as those with Budd-Chiari syndrome, Wilson disease, congestive liver disease, drug-induced liver injury, glycogen storage disease, hemochromatosis, or cryptogenic chronic liver disease were categorized in the Others (n = 208) group. Liver cirrhosis and comorbid diseases including diabetes, dyslipidemia, hypertension, and hyperuricemia were diagnosed by each physician in charge based on the clinical background and history. Liver cirrhosis was comprehensively diagnosed based on liver histological assessment, liver stiffness measurement measured by transient elastography, 22 the Fibrosis-4 (FIB-4) index, 23 aspartate aminotransferase-to-platelet ratio index (APRI), 24 and overt findings of cirrhosis such as ascites, jaundice, hepatic encephalopathy, and esophagogastric varices. Diabetes, hypertension, dyslipidemia, and hyperuricemia were diagnosed based on blood test value.
Statistical analyses
All statistical analyses were carried out using R Statistical Software (version 3.3.2; R Foundation for Statistical Computing, Vienna, Austria). The χ 2 -test was used to perform intergroup comparisons of categorical variables. The Mann-Whitney U-test or Wilcoxon's signed rank test was used for intergroup comparisons of continuous variables. A stepwise logistic regression model was used to undertake multivariate analyses for the factors associated with pruritus. Factors with data loss of 35% or more were excluded from the choice of independent variables.
In all analyses, a P-value of less than 0.05 was considered to be statistically significant.
Ethics
The Clinical Research Ethics Review Committee of each facility approved this study. An opt-out approach was used to obtain informed consent from the patients, and personal information was carefully protected during data collection.
RESULTS
Patient characteristics
T HE PATIENTS' CHARACTERISTICS are summarized in Table 1 . The median age was 60 years (range, 19-97 years), and 890 (54.6%) patients were women. There were 658 patients with pruritus and the prevalence of pruritus was 40.3%. Liver cirrhosis was significantly more frequent in patients with pruritus compared with patients who had no pruritus (37.8% vs. 32.7%, P = 0.036). In the lifestyle-related diseases, prevalence of dyslipidemia was significantly lower in patients with pruritus compared with those without pruritus (15.0% vs. 19.0%, P = 0.018). There was no statistically significant difference in the prevalence of diabetes or hyperuricemia. There was a tendency for a lower prevalence of hypertension in patients with pruritus than in those without pruritus (25.7% vs. 30.2%, P = 0.053). Among the liver function tests, alanine aminotransferase (ALT) levels were significantly higher in pruritus patients compared with those who had no pruritus. Aspartate aminotransferase (AST) levels in pruritus patients tended to be higher than those in patients without pruritus (28 U/L vs. 27 U/L, P = 0.055). Platelet counts and the prothrombin timeinternational normalized ratio were lower, and total bilirubin, APRI, and the FIB-4 index were higher in patients with pruritus than in those without pruritus, but these differences were not statistically significant. The presence of pruritus was significantly different depending on the underlying liver disease (P < 0.001).
Prevalence of pruritus
Prevalence of pruritus according to the underlying liver disease is summarized in Figure 2 . Overlap syndrome (60.0%) and PBC (51.4%) showed a relatively high prevalence of pruritus, whereas inactive HBV carriers (22.2%) and AIH (24.3%) showed a lower prevalence. The prevalence of pruritus in NAFLD and ALD was 44.7% and 34.2%, respectively.
Features of pruritus
The locations of pruritus on the body are summarized in Figure 3 . In the medical interview, patients chose from 15 locations to identify the itchy areas on their body (multiple answers were allowed). The most common location was on the back (63.1%). Small body parts such as hands (9.4%), groin (7.3%), fingers (4.0%), and toes (4.0%) showed a lower frequency of pruritus. The back was also the most common area of itchiness among all liver diseases (data not shown) and there was no sex difference (female vs. male: 64.7% vs. 60.7%, P = 0.296). Itching lasted longer than 6 months in 38.3% of patients with pruritus (Fig. 4) . There was no sex difference in the duration of pruritus (P = 0.487). Pruritus was more severe during the day than at night in overall patients (4 vs. 3, P < 0.001, Fig. 5a ), untreated patients (3 vs. 2, P < 0.001, Fig. 5b ), and patients with antipruritic agents (5 vs. 4.5, P < 0.001, Fig. 5c ) using the Wilcoxon signed rank test. There was a seasonal exacerbation in 45% (296/658) of patients, and 80% (237/296) of them reported exacerbation during the winter (Fig. 6 ). Exacerbation during winter was common among all liver diseases. Male patients reported an exacerbation during winter more than female patients (87.1% vs. 75.0%, P = 0.010). A total of 301 patients (45.7% of the patients with pruritus) received therapy with antipruritic agents. Among them, 70.7% (213/301) of patients received only external applications, 7.6% (23/301) received only oral medicines, and 12.3% (37/301) received both external applications and oral medicines. Patients subjectively reported the efficacy on pruritus as "great" in 36.5% (110/301), "partial" in 41.2% (124/301), or "null" in 16.6% (50/301) (Fig. 7) .
Factors associated with pruritus
Eighteen variables were chosen using a stepwise variable selection algorithm. Twelve factors (sex, age, body mass index, cirrhosis, platelet count, ALT, total bilirubin, direct bilirubin, creatinine, estimated glomerular filtration rate, FIB-4 index, and APRI) were excluded and six factors (etiology, diabetes, hypertension, hyperuricemia, AST, and blood urea nitrogen) were chosen to contribute to the multivariable logistic regression model. Active HBV infection (odds ratio [OR], 2.51; 95% confidence interval [CI], 1.068-6.432; P = 0.043), PBC (OR, 3.69; 95% CI, 1.286-11.337; P = 0.018), diabetes (OR, 1.57; 95% CI, 1.114-2.219; P = 0.010), and AST ≥60 U/L (OR, 2.06; 95% CI, 1.186-3.594; P = 0.011) were independent factors associated with pruritus in patients with chronic liver disease ( Table 2) .
DISCUSSION
Pruritus has not been sufficiently studied in patients with chronic liver disease. Our survey in a large cohort of patients with chronic liver disease identified that the overall prevalence of pruritus was 40.3% (658/1631), and 57.8% (174/301) were unresponsive to antipruritic agents. The prevalence of pruritus was different among the different etiologies of chronic liver disease, and the underlying chronic liver disease, comorbid diabetes, and AST level were significant factors associated with the presence of pruritus.
The prevalence of pruritus in ALD (34.2%), AIH (24.3%), and NAFLD (44.7%) were also reported in detail in this study. Our results showed that the prevalence of pruritus was 51.4% in PBC and 43% in overall HCV infection. These results are similar to previous reports. [5] [6] [7] 12 Koulentaki et al. carried out a prospective evaluation of dermatological manifestations in 49 PBC patients and 45 controls (age and sex matched) and pruritus was found in 69.3% of patients versus 22.2% of controls. 5 Rishe et al. reported that the prevalence of pruritus in PBC was 69.3% in 238 subjects. 6 Of 180 Japanese PBC patients who answered questions in the Japanese version of PBC-40, which is a disease-specific questionnaire for QOL, 34.4% gave their degree of pruritus as "none", 33.9% as "mild", 24.4% as "moderate", and 7.2% as "severe". Although the study cohorts and the methods to evaluate the severity of pruritus were different among the studies, pruritus is considered to be a common concomitant symptom of PBC. The prevalence of pruritus in viral hepatitis has been unclear. Suzuki et al. investigated the prevalence and severity of pruritus in 89 Japanese chronic hepatitis C patients treated with or without interferon (IFN) therapy and 55 controls without chronic liver disease using a VAS and a five-point scale. 12 The prevalence of nocturnal pruritus was 58.4% of patients ("mild" in 16.9%, "moderate" in 29.2%, "severe" in 12.4%, "very severe" in 0%) versus 5.5% of controls. The VAS score of the non-IFN group, the α2a group, and the α2b + ribavirin group was 1.13 ± 0.29, 1.01 ± 0.56, and 3.20 ± 0.27, respectively, all of which were significantly higher than the control group (0.32 ± 0.26). These data suggest that pruritus is a common symptom for patients with hepatitis C, and hepatitis C might cause pruritus independent from IFN therapy. The prevalence of pruritus in overall HBV infection (36.2%) was relatively higher than the previous report (8%). 11 However, it is difficult to compare our study to previous reports because only 49 patients were surveyed in the previous study and 31 of them had HIV co-infection. 11 Our analysis categorized patients with viral hepatitis according to the disease activity, and made the novel suggestion that chronic liver disease activity was associated the pruritus prevalence.
The prevalence of hypertension was lower in patients with pruritus compared with those without (25.7% vs. 30.2%, P = 0.053). Therefore, we speculate that there is a potential underlying clinical background that improves pruritus in patients with hypertension. The reninangiotensin system, which is associated with elevated blood pressure, relieves pain through the opioid system, and angiotensin II, which has pain-relieving actions, is related to activation of brain-localized AT2 receptors and release of endogenous opioids. 25 The pressure pain threshold is higher in hypertensive compared with normotensive older adults. 26 Consequently, hypertension increases the itching threshold. These findings might explain the lower prevalence of pruritus in the patients with hypertension in our study, whereas the therapeutic effect against hypertension remains unclear. Further investigation that includes information on antihypertensive agents is needed. In the present study, the prevalence of dyslipidemia was also lower in the patients with pruritus compared with those without pruritus (15.0% vs. 19.0%, P = 0.018). Cholesterol metabolism is closely related to the pathogenesis of chronic liver disease. Cholesterol synthesis is generally impaired according to the progression of chronic liver disease and hypolipidemia is a common concomitant finding of liver cirrhosis. 27 Hepatitis C virus infection increases hepatic steatosis and decreases serum levels of total cholesterol, low-density lipoprotein cholesterol (LDL-C), and apolipoprotein B.
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A rapid increase in the serum LDL-C concentration during IFN-free treatment for hepatitis C is frequently observed. 29 In the patients with dyslipidemia in our study, the prevalence of active HCV infection was 14.1% in the pruritus patients and 6.3% in the patients without pruritus (P = 0.025, data not shown). Therefore, we speculate that 
the higher prevalence of HCV infection, which mimics normolipidemia, might cause the lower prevalence of dyslipidemia in the patients without pruritus. Surprisingly, 54.3% patients with pruritus never received an antipruritic therapy. Pruritus severity of the untreated patients was significantly lower than the treated patients during the day (3 vs. 5, P < 0.001) and night (2 vs. 4.5, P < 0.001) (subanalysis from Fig. 5b ,c using the MannWhitney U-test). A possible explanation for the low treatment rate is that pruritus was less severe in untreated patients than in treated patients. In addition, physicians might be unaware of relatively non-severe pruritus in chronic liver disease.
The mechanism of pruritus is complicated and remains unclear. Neuropeptides, inflammatory cytokines, and immunoglobulin E regulate mast cells to secrete histamine, which causes itchiness. In chronic liver diseases, bile salt, steroids, histamine, lysophosphatidic acid, and opioids were previously shown to affect pruritus. 30, 31 Recently, opioids were reported to regulate pruritus in chronic liver diseases. Activation of μ-receptor signaling exacerbates pruritus and κ-opioid receptor signaling inhibits pruritus. 25 Therefore, μ-receptor agonists dominant state causes pruritus and κ-opioid receptor agonists have been developed as antipruritic agents. 32, 33 In our study, underlying chronic liver disease, diabetes, and AST level were independent factors associated with pruritus. Active HBV infection, but not chronic HCV infection, was an independent factor associated with pruritus, whereas the prevalence of pruritus in patients with active HBV infection (40.6%) was relatively lower than in patients with chronic HCV infection (45.9%). A possible explanation for this inverse result is the higher prevalence of the patients with AST ≥60 U/L in chronic HCV infection than active HBV infection (14.5% vs. 2.9%, P < 0.001), and chronic HCV infection could be a potential confounding factor for AST level, which was an independent factor associated with pruritus. Akuta et al. . Negativity for HBsAg (OR, 2.01; 95% CI, 1.35-3.00; P = 0.001) and the presence of hepatocellular carcinoma (OR, 1.82; 95% CI, 1.09-3.02; P = 0.022) were independent factors associated with pruritus using multivariate logistic regression analysis with HBsAg, hepatocellular carcinoma, and age as explanatory variables. 34 We identified six independent factors associated with pruritus in 1631 chronic liver disease patients using multivariate analysis (etiology, diabetes, hypertension, hyperuricemia, AST, and blood urea nitrogen) out of 18 factors chosen as explanatory variables by a stepwise variable selection algorithm. Our results confirmed that HBV activity and pathogenesis of chronic hepatitis B affects pruritus. More precise analysis including the effect of anti-HBV therapy on pruritus should be investigated further.
In our study, the serum AST level was an independent factor associated with pruritus. Tripathi et al. studied the dose-dependent effect of histamine on liver function markers in immunized rabbits and reported the elevation and peculiar changes of AST/ALT ratios by histamine. The authors suggested that histamine-mediated hepatocyte damage is associated with the elevation of AST levels 35 and is one of the possible mechanisms behind the AST level associated with pruritus in our study. Further study is required to identify whether known factors such as bile salt, steroids, lysophosphatidic acid, and opioids are 38 Interaction between diabetes and chronic liver diseases in the prevalence of pruritus has not been investigated. In our study, diabetes was an independent factor associated with pruritus. Thus, diabetes increases the risk of pruritus regardless of the presence or absence of chronic liver diseases, and the underlying mechanisms of pruritus in diabetes and chronic liver disease might be different.
Liver cirrhosis increases the severity of pruritus in PBC. 39 However, it is unclear whether advanced liver fibrosis affects the pathogenesis of pruritus in other chronic liver diseases. According to our results, the prevalence of cirrhosis was significantly higher in patients with pruritus compared with those without pruritus, but liver cirrhosis was not an independent factor associated with the prevalence of pruritus. Therefore, pruritus is not the only specific comorbid symptom of liver cirrhosis.
The prevalence of pruritus was reported to be 8.4% in a large population of 40 888 adults. 40 However, a detailed analysis had not been carried out including location of pruritus on the body, duration, circadian changes in pruritus severity, seasonal exacerbation, or therapeutic effect. Our study provides the following novel information: (i) the back is the most common location of pruritus; (ii) 38.5% of patients have pruritus for more than 6 months; (iii) pruritus is more severe during the day compared to night, with or without antipruritic treatment; (iv) 45% of patients report seasonal exacerbation of itchiness, especially in the winter; and (v) antipruritic agents fail to suppress itchiness in 57.8% of patients with pruritus.
Our survey was undertaken from January to June, and has the potential limitation of a seasonal bias in the patients' answers to the medical interview. A yearround interview is required to more precisely evaluate pruritus.
In conclusion, pruritus is a common comorbid symptom in chronic liver diseases, having a prevalence of 40.3%. Active HBV infection, PBC, AST ≥60 U/L, and comorbid diabetes are factors associated with pruritus. Patients should be questioned more about pruritus to improve their QOL.
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